Completed PHASE3 INTERVENTIONAL 3-arm NCT00548340

VEC-162 Study in Adult Patients With Primary Insomnia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 (20 mg/Day and 50 mg/Day) in the Treatment of Primary Insomnia

Sponsor: Vanda Pharmaceuticals

Conditions Primary Insomnia

Interventions Placebo VEC-162 20 mg VEC-162 50 mg

Updated 7 times since 2017 Last updated: Oct 8, 2014 Started: Nov 30, 2007 Primary completion: Feb 29, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary Insomnia and is currently completed. Vanda Pharmaceuticals leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vanda Pharmaceuticals

Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Austin, United States , Beachwood, United States , Birmingham, United States , Burbank, United States , Chesterfield, United States , Chevy Chase, United States , Chicago, United States , Cincinnati, United States and 25 more locations